Ocular Inflammation with Use of Oral Bisphosphonates

Purpose: To report a case of ocular inflammation after bisphosphonate use in a patient with osteoporosis.Case summary: A 54-year-old female presented to our clinic with eye pain and conjunctival and episcleral vessel injection in both eyes for 1 month. The patient was diagnosed with osteoporosis by the Department of Endocrinology 7 weeks ago and prescribed risedronate, a bisphosphonate. After using risedronate for 3 weeks, the patient developed generalized body pain, eye pain, and conjunctival injection. Slit lamp examination demonstrated conjunctival injection, whereas fundus examination did not reveal any cells in the anterior chamber or any other abnormal findings. Subsequently, risedronate was discontinued, which relieved the pain. At the 2-month follow-up visit in the outpatient department, the patient was asymptomatic, and there was no conjunctival injection.Conclusions: Bisphosphonates can lead to ocular adverse effects, which should be considered in patients with osteoporosis presenting with nonspecific ocular inflammation.

Authors

Institutions

Publication Details

Journal
Journal of the Korean Ophthalmological Society
Published
2025-02-15
DOI
https://doi.org/10.3341/jkos.2025.66.2.128
Primary Topic
Bone health and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ocular Inflammation with Use of Oral Bisphosphonates

Yu Cheol Kim, Kyung Tae Kang, Jee Hyun Jeong
Journal of the Korean Ophthalmological Society
Bone health and treatments
article

Ocular Inflammation with Use of Oral Bisphosphonates

Yu Cheol Kim, Kyung Tae Kang, Jee Hyun Jeong
article en

Abstract

Purpose: To report a case of ocular inflammation after bisphosphonate use in a patient with osteoporosis.Case summary: A 54-year-old female presented to our clinic with eye pain and conjunctival and episcleral vessel injection in both eyes for 1 month. The patient was diagnosed with osteoporosis by the Department of Endocrinology 7 weeks ago and prescribed risedronate, a bisphosphonate. After using risedronate for 3 weeks, the patient developed generalized body pain, eye pain, and conjunctival injection. Slit lamp examination demonstrated conjunctival injection, whereas fundus examination did not reveal any cells in the anterior chamber or any other abnormal findings. Subsequently, risedronate was discontinued, which relieved the pain. At the 2-month follow-up visit in the outpatient department, the patient was asymptomatic, and there was no conjunctival injection.Conclusions: Bisphosphonates can lead to ocular adverse effects, which should be considered in patients with osteoporosis presenting with nonspecific ocular inflammation.

Journal of the Korean Ophthalmological SocietyVol. 66(2)
Keimyung University (KR)
Openalex Percentile: Top 96%
Bone health and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ocular Inflammation with Use of Oral Bisphosphonates — Yu Cheol Kim, Kyung Tae Kang, et al. · Journal of the Korean Ophthalmological Society (2025) | TGRS Research Map | TGRS